"Sarepta Is Undervalued Even Without Eteplirsen Accelerated Approval"
The above referenced article was published on 3-5-13 by thestreet. Just google the title and read it. The author (not Adam F. - who is overly vilified) makes an excellent case for the long view of SRPT.
I am unconcerned about the recent pull-back due to FDA's wanting to look at all recent data. If you believe the author's thesis, as I do, you just can't get all lathered up by this recent sell-off, which has been compounded by sell-side analysts holding conference calls, beating the drum for the bear case (more FDA required clinical testing).
And to Bud's T/A work. What about the case for manipulation of share price due to concerted effort by the short crowd, which triggers a "sell signal" when a certain support level has been violated? I've seen this whip-saw effect in biotech happen many times before, where stops get taken out quickly, only to have the shorts cover and the share price recovers. It's a messy industry, with a lot of potential for manipulation. It's just the nature of the beast.